5 results on '"Alonso-Salinas GL"'
Search Results
2. Smartwatch ECG Tracing and Ischemic Heart Disease: ACS Watch Study.
- Author
-
Buelga Suárez M, Pascual Izco M, Pastor Pueyo P, Lozano Granero C, García Montalvo J, and Alonso Salinas GL
- Subjects
- Humans, Arrhythmias, Cardiac diagnosis, Electrocardiography, Hospitalization, Myocardial Ischemia diagnosis
- Abstract
Background: Smartwatches have become a widely used tool for health self-care. Its role in ischemic heart disease (IHD) has not been assessed. Objetcive: The aim of this study was to evaluate the usefulness of smartwatch ECG registry in IHD., Methods: We present an observational study of 25 consecutive patients with acute IHD. Conventional ECG and smartwatch tracing were obtained simultaneously at admission. Waves of conventional and smartwatch ECGs were objectively compared. A survey on medical attitude was conducted among 12 physicians (3 cardiologists, 3 intensivists, 3 emergency physicians, and 3 general practitioners) and a score (1-5) of concordance between the records was requested., Results: There were no differences in Q-wave, R-wave, ST segment, or T-wave. There was a very strong correlation between ST segments, a strong correlation in Q-waves and R-waves, and a moderate correlation in T-wave measurements. All specialists obtained a high level of agreement (4.45 ± 0.45). Smartwatch tracings would lead to similar management compared to conventional ECG. There were only 6 (2%) discrepant cases due to differences in inferior repolarization, showing an almost perfect agreement (kappa = 0.96)., Conclusions: In most patients with acute IHD, smartwatch ECG tracing is a reliable tool to make the diagnosis and guide appropriate medical care. However, due to their intrinsic limitations, inferior myocardial infarctions may be missed and require a conventional 12-lead ECG to rule them out., (© 2022 S. Karger AG, Basel.)
- Published
- 2023
- Full Text
- View/download PDF
3. Heart Failure in the Time of COVID-19.
- Author
-
Jiménez-Blanco Bravo M, Cordero Pereda D, Sánchez Vega D, Del Prado Díaz S, Monteagudo Ruiz JM, Zamorano Gómez JL, and Alonso Salinas GL
- Subjects
- Aged, Aged, 80 and over, Betacoronavirus, COVID-19, Clinical Protocols, Female, Humans, Male, Middle Aged, Public Health Surveillance, SARS-CoV-2, Spain epidemiology, Coronavirus Infections prevention & control, Emergency Service, Hospital statistics & numerical data, Heart Failure mortality, Outpatients statistics & numerical data, Pandemics prevention & control, Patient Admission statistics & numerical data, Pneumonia, Viral prevention & control
- Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as a new threat to healthcare systems. In this setting, heart failure units have faced an enormous challenge: taking care of their patients while at the same time avoiding patients' visits to the hospital., Objective: The aim of this study was to evaluate the results of a follow-up protocol established in an advanced heart failure unit at a single center in Spain during the coronavirus disease 2019 (COVID-19) pandemic., Methods: During March and April 2020, a protocolized approach was implemented in our unit to reduce the number of outpatient visits and hospital admissions throughout the maximum COVID-19 spread period. We compared emergency room (ER) visits, hospital admissions, and mortality with those of January and February 2020., Results: When compared to the preceding months, during the COVID pandemic there was a 56.5% reduction in the ER visits and a 46.9% reduction in hospital admissions, without an increase in mortality (9 patients died in both time periods). A total of 18 patients required a visit to the outpatient clinic for decompensation of heart failure or others., Conclusion: Our study suggests that implementing an active-surveillance protocol in acutely decompensated heart failure units during the SARS-CoV-2 pandemic can reduce hospital admissions, ER visits and, potentially, viral transmission, in a cohort of especially vulnerable patients., (© 2020 S. Karger AG, Basel.)
- Published
- 2020
- Full Text
- View/download PDF
4. Inflammatory Pathways in Acute Myocardial Infarction: A Matter of Prime Importance.
- Author
-
Alonso Salinas GL, Pascual Izco M, and Zamorano JL
- Subjects
- Down-Regulation, Humans, Ventricular Remodeling, Circulating MicroRNA, MicroRNAs, Myocardial Infarction, ST Elevation Myocardial Infarction
- Published
- 2017
- Full Text
- View/download PDF
5. Clinical Experience with Ivabradine in Acute Heart Failure.
- Author
-
Pascual Izco M, Alonso Salinas GL, Sanmartín Fernández M, Del Castillo Carnevalli H, Jiménez Mena M, Camino López A, and Zamorano Gómez JL
- Subjects
- Acute Disease, Aged, Blood Pressure, Female, Heart Failure physiopathology, Heart Rate, Hospitalization, Humans, Ivabradine, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Benzazepines therapeutic use, Cardiovascular Agents therapeutic use, Heart Failure drug therapy
- Abstract
Objective: Ivabradine has been shown to improve symptoms and to reduce rehospitalization and mortality in patients with severe chronic heart failure (HF). Its indication in acute HF is not clear. Acute HF patients could also benefit from HR reduction, as myocardial consumption and oxidative stress are related to tachycardia. Moreover, beta-blockers are contraindicated in cardiogenic shock and should not be initiated with congestive signs. Accordingly, we evaluated the role of ivabradine in acute HF patients., Methods: This was a retrospective analysis of 29 consecutive patients treated for acute HF in the Cardiac ICU, and for whom ivabradine was initiated during hospitalization between January 2011 and January 2014. All patients were in sinus rhythm and had a heart rate (HR) >70 bpm. Catecholamine use was necessary in 16 patients (57.1%) during the hospitalization, in 14 (87.5%) of these before ivabradine treatment., Results: Systolic blood pressure showed no variation during the first 24 h of ivabradine administration or at discharge. HR showed an absolute reduction of 10 bpm at 6 h (p < 0.001), 11 bpm at 24 h (p = 0.004) and 19 bpm (p < 0.001) at discharge. No episodes of significant bradycardia or hypotension were recorded after starting the drug., Conclusions: HR reduction with ivabradine in acute HF is well tolerated. It represents an attractive option, especially when there is excessive catecholamine-related tachycardia; this should be appropriately evaluated in randomized trials., (© 2016 S. Karger AG, Basel.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.